The 48th annual meeting of the European Association for the analysis of the Liver.

Abstracts on Bristol-Myers Squibb’s analysis in liver disease accepted for presentation Bristol-Myers Squibb Company announced today that 14 abstracts on the Business's research in liver disease have already been accepted for presentation at The International Liver CongressTM 2013, the 48th annual meeting of the European Association for the analysis of the Liver , in Amsterdam, 24 – 28 April. The regimen has been studied as a potential interferon alfa-, ribavirin – and ritonavir-free treatment option to prevent the tolerability and drug-drug interaction profiles of the medicines.Barnett suggests that academic institutions should establish zones that are free of convenience stores and work harder to compete against fast food chains.

AcelRx commences third ARX-01 Phase 3 study in post-operative pain AcelRx Pharmaceuticals, Inc. , a specialty pharmaceutical organization focused on the advancement and commercialization of innovative therapies for the treating acute and breakthrough discomfort, today announced dosing of the initial patient in the third of three planned Phase 3 studies for ARX-01, the Sufentanil NanoTab PCA System, its novel sublingual patient-controlled analgesia program.